Lundbeck to acquire Prexton Therapeutics

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay EUR 100m upfront and is furthermore required to later pay up to EUR 805m in development and sales milestones to the group of current owners. By acquiring Prexton, Lundbeck will obtain global rights of foliglurax, which currently is in clinical phase II testing for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). The aim is to treat the motor symptoms of Parkinson’s disease, such as resting tremor and dyski-nesia.

VISCHER advised Lundbeck as lead-counsel in this transaction. The team was led by Corporate partners Christian Wyss and Robert Bernet and included Luzius Zumstein, Gian Caprez, Gian Geel, Aron Waltuch (all Corporate), Marc Prinz (Employment) and Eric Flückiger (Tax).

Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Deals & Cases